Damora Therapeutics, Inc. (DMRA) annual balance sheet — 8-year assets, liabilities & equity history
Damora Therapeutics, Inc. (DMRA) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 531.32M | 260.42M | 16.84M | 36.77M | 63.91M | 110.1M | 169.29M | 56.08M | 34.96M |
| Cash & Short-Term Investments | 528.48M | 257.62M | 14.18M | 33.15M | 60.22M | 100.19M | 163.58M | 11.29M | 30.99M |
| Cash Only | 349.66M | 257.62M | 14.18M | 21.46M | 32.79M | 62.56M | 163.58M | 11.29M | 30.99M |
| Short-Term Investments | 178.82M | 0 | 0 | 11.69M | 27.44M | 37.63M | 0 | 0 | 0 |
| Accounts Receivable | 838K | 899K | 881K | 1.72M | 1.38M | 2.28M | 2.21M | 41.13M | 989K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 469K | 1.32M | 1.19M | 1.13M | 1.5M | 5.9M | 1.86M | 3.66M | 2.98M |
| Total Non-Current Assets | 1.31M | 104K | 293K | 1.45M | 9.28M | 12.11M | 2.3M | 529K | 144K |
| Property, Plant & Equipment | 830K | 104K | 130K | 325K | 1.17M | 1.04M | 885K | 298K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 5.83M | 9.05M | 254K | 231K | 144K |
| Other Non-Current Assets | 480K | 0 | 163K | 1.13M | 2.28M | 2.03M | 1.16M | 0 | 0 |
| Total Assets | 532.63M | 260.53M | 17.13M | 38.23M | 73.19M | 122.22M | 171.6M | 56.61M | 35.1M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Asset Growth % | 13537.41% | 1420.7% | -55.18% | -47.77% | -40.12% | -28.78% | 203.12% | 61.26% | - |
| Total Current Liabilities | 35.89M | 20.07M | 1.2M | 5.83M | 11.11M | 4.54M | 5.57M | 7.93M | 4.44M |
| Accounts Payable | 6.08M | 444K | 377K | 1.7M | 3.35M | 1.53M | 2.85M | 3.33M | 1.41M |
| Days Payables Outstanding | 12.51K | - | 760.25 | 748.47 | 2.5K | 1.27K | 5.54K | 10.95K | - |
| Short-Term Debt | 0 | 0 | 12K | 183K | 476K | 399K | 374K | 87K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.82M | 1.52M | 604K | 2.96M | 6.68M | 2.01M | 1.31M | 4.4M | 2.88M |
| Current Ratio | 14.80x | 12.98x | 14.07x | 6.31x | 5.75x | 24.23x | 30.42x | 7.07x | 7.87x |
| Quick Ratio | 14.80x | 12.98x | 14.07x | 6.31x | 5.75x | 24.23x | 30.42x | 7.07x | 7.87x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 974K | 81K | 1.46M | 66K | 328K | 448K | 541K | 211K | 0 |
| Long-Term Debt | 0 | 0 | 1.36M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 999K | 53K | 61K | 66K | 328K | 448K | 541K | 211K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 28K | 28K | 43K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 36.87M | 20.15M | 2.66M | 5.9M | 11.44M | 4.99M | 6.11M | 8.14M | 4.44M |
| Total Debt | 1.1M | 68K | 1.43M | 249K | 804K | 847K | 915K | 298K | 0 |
| Net Debt | -348.56M | -257.56M | -12.74M | -21.22M | -31.98M | -61.72M | -162.67M | -11M | -30.99M |
| Debt / Equity | 0.00x | 0.00x | 0.10x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.15x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | -4.35x |
| Total Equity | 495.76M | 240.38M | 14.47M | 32.33M | 61.75M | 117.22M | 165.49M | 48.47M | 30.66M |
| Equity Growth % | 18199.19% | 1561.12% | -55.24% | -47.64% | -47.32% | -29.17% | 241.42% | 58.09% | - |
| Book Value per Share | 30.29 | 176.36 | 12.51 | 30.42 | 60.76 | 116.01 | 163.77 | 47.64 | 30.14 |
| Total Shareholders' Equity | 495.76M | 240.38M | 14.47M | 32.33M | 61.75M | 117.22M | 165.49M | 48.47M | 30.66M |
| Common Stock | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -578.31M | -487.36M | -277.52M | -256.08M | -217.74M | -156.11M | -104.36M | -69.52M | -33.02M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -233K | 802K | 97K | 380K | -244K | -320K | 674K | -2.45M | -1.64M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DMRA stock.
As of 2025, Damora Therapeutics, Inc. (DMRA) had total assets of $260.5M including $260.4M in current assets.
Damora Therapeutics, Inc. (DMRA) carries total debt of $0.1M, offset by $257.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Damora Therapeutics, Inc. (DMRA) has total shareholders' equity (book value) of $240.4M ($176.36 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Damora Therapeutics, Inc. (DMRA) reported a current ratio of 12.98x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.